PBYI Q2 2019 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$299M

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$54M+6.2% YoY

Gross Profit

$45M82.7% margin

Operating Income

-$26M-47.8% margin

Net Income

-$37M-69.4% margin

EPS (Diluted)

$-0.97

QoQ Revenue Growth

-45.6%

Cash Flow

Operating Cash Flow

$44M

Free Cash Flow

$44M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$240M

Total Liabilities

$218M

Stockholders' Equity

$22M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$54M	$51M	+6.2%
Gross Profit	$45M	$42M	+6.4%
Operating Income	-$26M	-$41M	+37.8%
Net Income	-$37M	-$44M	+15.6%

Revenue Segments

Product

$54M100%

Royalty

$55,0000%